PE20040306A1 - THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES - Google Patents

THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES

Info

Publication number
PE20040306A1
PE20040306A1 PE2003000315A PE2003000315A PE20040306A1 PE 20040306 A1 PE20040306 A1 PE 20040306A1 PE 2003000315 A PE2003000315 A PE 2003000315A PE 2003000315 A PE2003000315 A PE 2003000315A PE 20040306 A1 PE20040306 A1 PE 20040306A1
Authority
PE
Peru
Prior art keywords
derivatives
therapeutic methods
sapogenins
cognitive
neurodegeneration
Prior art date
Application number
PE2003000315A
Other languages
Spanish (es)
Inventor
Philip James Gunning
Yaer Hu
Daryl Rees
Zongqin Xia
Antonia Orsi
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP020101170A external-priority patent/AR033079A1/en
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of PE20040306A1 publication Critical patent/PE20040306A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)

Abstract

The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.
PE2003000315A 2002-03-27 2003-03-27 THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES PE20040306A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ARP020101170A AR033079A1 (en) 2001-03-28 2002-03-27 SAPOGENINE DERIVATIVES, SYNTHESIS AND USE, AND METHODS BASED ON USE
US36817802P 2002-03-28 2002-03-28
PCT/GB2002/001578 WO2002079221A2 (en) 2001-03-28 2002-03-28 Sapogenin derivatives, their synthesis and use

Publications (1)

Publication Number Publication Date
PE20040306A1 true PE20040306A1 (en) 2004-05-29

Family

ID=30001210

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000315A PE20040306A1 (en) 2002-03-27 2003-03-27 THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES

Country Status (10)

Country Link
KR (1) KR20100093621A (en)
CN (1) CN1642558B (en)
AT (1) ATE424211T1 (en)
IL (1) IL164161A0 (en)
NZ (2) NZ547897A (en)
PE (1) PE20040306A1 (en)
PL (1) PL213697B1 (en)
RU (1) RU2332999C2 (en)
TW (1) TWI329016B (en)
WO (1) WO2003082893A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861788B2 (en) * 2003-06-03 2005-03-01 Motorola, Inc. Switchable display/mirror method and apparatus
FR2868700B1 (en) * 2004-04-09 2008-09-26 Michel Coisy USE OF DOPAMINE OR ITS BIOLOGICAL PRECURSORS AGAINST ALGONURODYSTRPHY.
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
HUE035328T2 (en) 2005-10-28 2018-05-02 Univ Industry Cooperation Group Kyung Hee Univ Extract of the family dioscoreaceae and composition for preventing or treating peripheral neuropathy comprising the same
JP2012515754A (en) 2009-01-24 2012-07-12 ファイトファーム ピーエルシー Treatment of neurotrophic factor mediated diseases
CN103189056A (en) * 2010-07-20 2013-07-03 植物药物公共有限公司 Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders
EP4245369A3 (en) 2011-09-08 2023-11-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CU20110244A7 (en) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem SPI-ESTEROID SYSTEMS WITH NEUROACTIVE AND ANTI-INFLAMMATORY EFFECTS
US11319338B2 (en) 2012-04-03 2022-05-03 Goldporp Pharma Limited Timosaponin compounds
CN112375115A (en) 2013-03-13 2021-02-19 萨奇治疗股份有限公司 Neuroactive steroids and methods of use thereof
CN103232520A (en) * 2013-05-13 2013-08-07 中国药科大学 Spirosteroid compounds and preparation method and medical application thereof
ES2970222T3 (en) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxysterols and procedures for their use
BR112018000129B1 (en) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Oxysterol compounds, their uses and pharmaceutical composition
MA42409A (en) 2015-07-06 2018-05-16 Sage Therapeutics Inc OXYSTEROLS AND THEIR METHODS OF USE
JP2018519328A (en) 2015-07-06 2018-07-19 セージ セラピューティクス, インコーポレイテッド Oxysterols and methods of their use
DK3436022T3 (en) 2016-04-01 2022-06-20 Sage Therapeutics Inc OXYSTEROLS AND PROCEDURES FOR USE THEREOF
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (en) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
CN110023323A (en) 2016-09-30 2019-07-16 萨奇治疗股份有限公司 The oxygen sterol that C7 replaces and its method as NMDA regulator
AU2017345399B2 (en) 2016-10-18 2022-02-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MX2019004578A (en) 2016-10-18 2019-10-09 Sage Therapeutics Inc Oxysterols and methods of use thereof.
CN108264535A (en) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 A kind of antidepressant compounds and its preparation method and application
RU2635485C1 (en) * 2017-03-21 2017-11-13 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Method for optic nerve atrophy treatment after craniocerebral injury
CN109988218B (en) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 Sarsasapogenin derivative and preparation method and application thereof
EP3572085A1 (en) * 2018-05-25 2019-11-27 Neuro-Sys Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN112457362B (en) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 Halogenated tetracyclic triterpene derivative and preparation and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3416112A1 (en) * 1984-04-30 1985-10-31 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen USE OF STEROLINES AND SPIROKETALINES AS LIPOXYGENAS REGULATORS
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH05246866A (en) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk Agent for stimulating cerebral metabolism and for improving cerebral function
DE4303214A1 (en) * 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
TW479061B (en) * 1993-12-24 2002-03-11 Mitsubishi Chem Corp Sialic acid derivatives
JPH092957A (en) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp Therapeutic and preventing agent for peripheral neuropathy
JPH092956A (en) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp Therapeutic and preventing agent for neuropathy
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
CN1131237C (en) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 Usage of steroi saponin for preventing and curing senile dementia and new steroid saponin
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
BR9909109A (en) * 1998-03-26 2000-12-12 Phytopharm Plc Uses of one or more among smilagenin, pleasedigenin, an astragaloside, tigogenin, ruscogenin, hecogenin, diogenin, smilagenin, anzurogenin d or an astragaloside and an extract from a plant of the genus smilax, asparagus, anemarrhena, yucca, yucca or yucca. for the treatment of a condition distinguished by a deficiency in the function or the number of membrane-bound postsynaptic receptors, pharmaceutical composition, and, processes to enhance cognitive function in a human or non-human animal and in a patient suffering from an age-related cognitive impairment, and to treat a condition distinguished by a deficiency in function or the number of membrane-bound receptors in a tissue, organ, cell type or organelle
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
JP2002030096A (en) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd Agent for regenerating neurocyte process and method for producing the same
EP1496913A4 (en) * 2002-03-15 2007-10-31 Samaritan Pharmaceuticals Inc Neuroprotective spirostenol pharmaceutical compositions

Also Published As

Publication number Publication date
CN1642558A (en) 2005-07-20
RU2332999C2 (en) 2008-09-10
TWI329016B (en) 2010-08-21
PL213697B1 (en) 2013-04-30
CN1642558B (en) 2012-05-30
WO2003082893A2 (en) 2003-10-09
WO2003082893A3 (en) 2004-04-15
NZ547344A (en) 2007-11-30
WO2003082893A8 (en) 2003-12-31
RU2004130281A (en) 2006-01-20
NZ547897A (en) 2008-02-29
IL164161A0 (en) 2005-12-18
TW200400042A (en) 2004-01-01
PL372941A1 (en) 2005-08-08
KR20100093621A (en) 2010-08-25
ATE424211T1 (en) 2009-03-15

Similar Documents

Publication Publication Date Title
PE20040306A1 (en) THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES
TR200700134T1 (en) Derivatives of sapogenin, their synthesis and usage, methods of their use.
HK1046912A1 (en) Substituted sapogenins and their use
HRP20080467A2 (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
DK1719512T3 (en) Sarsasapogenin and smilagenin for the treatment of cognitive dysfunction
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
BR0309665A (en) Treatment of alpha-galactosidase deficiency at
DE60108857D1 (en) METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ALPHA-ADRENEER RECEPTORS
EP2301625A3 (en) Compositions and methods for treating cognitive disorders
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
GB9923078D0 (en) Sapogenin derivatives and their use
WO2004007531A3 (en) Activated checkpoint therapy and methods of use thereof
TR200101149T2 (en) Treatment of external retinal disorders.
HRP20041009A2 (en) Theraputic methods and uses of sapogenins and their derivatives
TW200833344A (en) Therapeutic methods and uses of sapogenins and their derivatives
UA85187C2 (en) 2-aminobenzoyl derivatives
BR0308788A (en) Therapeutic processes and uses of sapogenins and their derivatives
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
WO2004073631A3 (en) Combination therapy for the treatment of neoplasms

Legal Events

Date Code Title Description
FC Refusal